Japan’s MHLW To Review Fertility Grant Conditions
This article was originally published in PharmAsia News
A Japan MHLW Committee decided for the first time to discuss whether the subsidized treatment costs for infertility treatment should be revised based on age and number of treatments for patients.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.